PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30503610-1	2019	beta2-microglobulin (B2M), a component of major histocompatibility complex class I, plays an important role in host immune reaction to tumor, and inactivation of B2M is known to contribute to resistance to immune checkpoint blockade (ICB) treatment.	indole-2-carboxylic acid	234-237	beta-2-microglobulin	Homo sapiens	0-19	
30503610-1	2019	beta2-microglobulin (B2M), a component of major histocompatibility complex class I, plays an important role in host immune reaction to tumor, and inactivation of B2M is known to contribute to resistance to immune checkpoint blockade (ICB) treatment.	indole-2-carboxylic acid	234-237	beta-2-microglobulin	Homo sapiens	21-24	
30503610-1	2019	beta2-microglobulin (B2M), a component of major histocompatibility complex class I, plays an important role in host immune reaction to tumor, and inactivation of B2M is known to contribute to resistance to immune checkpoint blockade (ICB) treatment.	indole-2-carboxylic acid	234-237	beta-2-microglobulin	Homo sapiens	162-165	
30503610-4	2019	Of note, bi-allelic B2M alterations, which had been known to be accumulated during ICB treatment, were frequently found (3/9) in ICB treatment-naive CRCs.	indole-2-carboxylic acid	83-86	beta-2-microglobulin	Homo sapiens	20-23	
30503610-4	2019	Of note, bi-allelic B2M alterations, which had been known to be accumulated during ICB treatment, were frequently found (3/9) in ICB treatment-naive CRCs.	indole-2-carboxylic acid	129-132	beta-2-microglobulin	Homo sapiens	20-23	
30503610-7	2019	Our results show that B2M mutation is common in MSU CRCs, which is one of the main targets for ICB treatment, suggesting that frequent B2M mutation status should be reminded for MSU CRCs in patient selection of ICB.	indole-2-carboxylic acid	95-98	beta-2-microglobulin	Homo sapiens	22-25	
30503610-7	2019	Our results show that B2M mutation is common in MSU CRCs, which is one of the main targets for ICB treatment, suggesting that frequent B2M mutation status should be reminded for MSU CRCs in patient selection of ICB.	indole-2-carboxylic acid	211-214	beta-2-microglobulin	Homo sapiens	22-25